Management of STEMI in low- and middle-income countries

Glob Heart. 2014 Dec;9(4):469-510. doi: 10.1016/j.gheart.2014.11.001.

Authors

Ragavendra R Baliga¹, Vinay K Bahl², Thomas Alexander³, Ajit Mullasari⁴, Pravin Manga⁵, G William Dec⁶, Jagat Narula⁷

Affiliations

¹ Division of Cardiovascular Medicine, Wexner Medical Center, The Ohio State University, Columbus, OH, USA. Electronic address: rrbaliga@gmail.com.
² Department of Cardiology, All India Institute of Medical Sciences, New Delhi, India.
³ Kovai Medical Center and Hospital, Coimbatore, India.
⁴ Madras Medical Mission, Chennai, India.
⁵ Division of Cardiology, Department of Medicine, University of Witwatersrand, Johannesburg, South Africa.
⁶ Cardiology Division, Massachusetts General Hospital Heart Center, Harvard Medical School, Boston, MA, USA.
⁷ Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

PMID: 25592801
DOI: 10.1016/j.gheart.2014.11.001

No abstract available

MeSH terms

Adrenergic beta-Antagonists / therapeutic use
Angiotensin-Converting Enzyme Inhibitors / therapeutic use
Anticoagulants / therapeutic use
Biomarkers / blood
Developing Countries / economics*
Electrocardiography / methods*
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use
Myocardial Infarction / blood
Myocardial Infarction / drug therapy*
Myocardial Infarction / economics
Myocardial Reperfusion / methods
Platelet Aggregation Inhibitors / therapeutic use
Poverty
Purinergic P2Y Receptor Antagonists / therapeutic use
Risk Assessment
Social Class

Substances

Adrenergic beta-Antagonists
Angiotensin-Converting Enzyme Inhibitors
Anticoagulants
Biomarkers
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Platelet Aggregation Inhibitors
Purinergic P2Y Receptor Antagonists